International Journal of Endocrinology / 2014 / Article / Tab 1

Review Article

A Review on the Relationship between SGLT2 Inhibitors and Cancer

Table 1

SGLT2 inhibitors under phase II and phase III clinical trials.

DrugCompanyPhase of clinical trial

Dapagliflozin (BMS-512148)Bristol-Myers Squibb/AstraZenecaPhase III (approved in Australia (Oct 2012), Europe (Nov 2012), Mexico (Mar 2013), New Zealand (June 2013), Brazil (July 2013), Argentina (Sep 2013), US (Jan 2014), and Japan (Mar 2014))

Canagliflozin (TA-7284, JAJ-28431754)Johnson and Johnson and Mitsubishi Tanabe PharmaPhase III (approved in US (Mar 2013) and Europe (Nov 2013))

Empagliflozin (BI-10773)Boehringer Ingelheim/LillyPhase III (approved in Europe (May 2014))

Ipragliflozin (ASP-1941)Astellas Pharma and Kotobuki Pharmaceutical CompanyPhase III (approved in Japan (Jan 2014)

Tofogliflozin (CSG452)Roche/ChugaiPhase III

Luseogliflozin (TS-071)TaishoPhase III

BI 44847Boehringer IngelheimPhase III

LX4211Lexicon PharmaceuticalPhase II

PF-04971729PfizerPhase II

EGT0001442TheracosPhase II

GW 869682 GlaxoSmithKlinePhase II

From [17, 19].